US Patent 10,570,453: Scope, Claim Structure, and US Patent Landscape for CERKL/rs993648-Guided Iloperidone Dosing for QT Risk
What does US 10,570,453 claim, in practical terms?
US 10,570,453 claims a personalized dosing method for iloperidone (and/or an iloperidone metabolite, or pharmaceutically acceptable salt) based on a CERKL expression product characterization and a specific genotype at rs993648 (with QT-prolongation risk stratification). The method is defined by conditional administration at two dose levels depending on the QT risk association of the characterized CERKL expression product, with explicit genotype qualifiers tied to “AG” vs “non-AG” at rs993648.
Core claim construct (Claim 1)
Claim 1 is a three-part conditional dosing workflow:
- Biomarker characterization
- Obtain a biological specimen from a human individual
- Characterize an expression product of the individual’s CERKL gene
- Conditional branch: CERKL expression product association with QT risk
-
If the characterized CERKL expression product is not associated with increased QT prolongation
→ administer a first quantity of:
- iloperidone, or
- an iloperidone metabolite, or
- a pharmaceutically acceptable salt
-
If the characterized CERKL expression product is associated with increased QT prolongation
→ administer a second quantity that is less than the first quantity, using the same drug forms
- Genotype constraint at rs993648
- The claim includes genotype-level limitation tied to QT risk status:
- one branch: rs993648 genotype is AG and is not associated with increased QT prolongation
- the other branch: rs993648 genotype is non-AG and is associated with increased QT prolongation
This makes Claim 1 both:
- biomarker-expression-method (CERKL expression product characterization), and
- SNP-genotype method (rs993648 AG vs non-AG) that anchors the QT-risk determination.
Quantitative limitation (Claims 2 and 3)
- Claim 2: first quantity can be 24 mg/day
- Claim 3: second quantity is less than 24 mg/day
So the patent’s dosing envelope, as written, is at least:
- a “full” dose: 24 mg/day
- a “reduced” dose: < 24 mg/day (numeric endpoint not further defined in the provided claim set)
Disease context limitation (Claim 4)
- Claim 4: the individual is suffering from long QT syndrome (LQTS)
That ties the method to a high-risk population where QT prolongation risk is clinically relevant.
Additional pharmacogenomic step (Claim 5)
- Claim 5: further comprising determining the individual’s CYP2D6 genotype
This expands the method into multi-biomarker/multi-gene decision-making: CERKL/rs993648 and CYP2D6.
What is the claim scope and where are the edges?
The scope is defined by what the method requires, not what it merely permits. The practical “infringement map” depends on each required element:
Required elements to practice Claim 1
A method practicing all of the following is within Claim 1 scope:
- A human subject treatment decision
- A specimen-based step characterizing CERKL expression product
- A conditional decision rule based on whether that CERKL expression product is associated with increased QT prolongation
- Administration of iloperidone (or metabolite/salt) at two different quantities:
- first quantity for the “not increased QT risk” status
- second quantity that is lower for the “increased QT risk” status
- A genotype limitation at rs993648 that maps:
- AG genotype to “not associated with increased QT prolongation”
- non-AG genotype to “associated with increased QT prolongation”
The strongest scope anchors
- Drug identity: iloperidone and its metabolite/salt are expressly covered.
- Biomarker identity: CERKL expression product characterization is expressly required.
- Genetic locus identity: rs993648 genotype is expressly used to map QT risk.
- Dose relationship: second quantity is explicitly lower than first quantity.
- Population limitation in dependent claim: LQTS status in Claim 4.
- Additional gene in dependent claim: CYP2D6 genotype determination in Claim 5.
Key boundary conditions (what matters most for design-arounds)
These are the claim elements that most constrain third-party practice:
-
CERKL expression product characterization is required.
A method that uses rs993648 genotype alone without characterizing CERKL expression product does not track the method language provided.
-
The rs993648 genotype mapping is explicitly recited.
If a competitor uses a different SNP or a different genotype-QT risk mapping, they avoid the precise limitation.
-
Dose relationship is conditional and must reduce the dose when risk is associated.
If a method does not reduce dose for the “increased risk” group, it does not fit the second-quantity less-than-first structure.
-
Iloperidone is explicitly the administered drug.
Substituting another antipsychotic outside the iloperidone/metabolite/salt definition moves outside the literal scope of the provided claims.
What does the dependency chain imply about enforceability strategy?
Even with only five claims provided, the dependency structure indicates how enforceability could be segmented:
Claim 1 (independent) is broadest
- Covers the full decision process anchored to CERKL expression product characterization + rs993648 genotype mapping + two-dose conditional administration of iloperidone.
Claims 2 and 3 narrow dose endpoints
- Claim 2 pins the first quantity to 24 mg/day.
- Claim 3 requires the second quantity to be < 24 mg/day.
If a real-world dosing regimen uses different first-dose values, Claim 1 might still be implicated, while Claims 2/3 would be harder to assert.
Claim 4 adds LQTS status
- If clinical use targets a non-LQTS population, Claim 4 does not apply, but Claim 1 might still apply depending on how “increased risk of QT prolongation” is operationalized in the method.
Claim 5 adds CYP2D6 genotype determination
- A method that omits CYP2D6 genotype determination may still fall within Claim 1 but not Claim 5.
How does the patent’s subject matter fit into a broader US patent landscape for iloperidone QT risk and pharmacogenomics?
Within the US landscape, iloperidone is a known QT-prolongation concern drug class. Patent strategies typically cluster around:
- dose adjustment rules,
- genetic predictors of QT prolongation or metabolizer status,
- CYP2D6/CYP3A4-linked exposure management for antipsychotics,
- electrophysiology biomarkers or genotype panels.
US 10,570,453 specifically differentiates itself by requiring:
- CERKL gene expression product characterization, and
- rs993648 genotype mapping for QT risk stratification,
- coupled to dosing reduction.
This is a different axis than exposure-only models centered on CYP2D6 metabolism. Claim 5 further aligns with the CYP2D6 landscape but keeps CERKL/rs993648 as the QT decision anchor.
Landscape implications for freedom-to-operate (FTO)
From a practical FTO standpoint, parties evaluating CERKL/rs993648-guided iloperidone dosing in the US would need to test whether earlier patents cover:
- CERKL-linked QT risk, or
- rs993648 genotype QT risk, or
- iloperidone dosing reduction based on those biomarkers,
- combined CERKL expression + rs993648 genotype workflows, and
- CYP2D6 genotype add-ons.
Because the claim language includes both a CERKL expression characterization step and an rs993648 genotype limitation, an earlier patent that covers only rs993648 genotype, without CERKL expression product characterization, may not necessarily overlap Claim 1 literal scope as presented. Conversely, a broader earlier method claiming biomarker-guided dosing using either CERKL expression alone or rs993648 genotype alone would create a higher risk of claim mapping via doctrine of equivalents arguments (not analyzed here because the claim text alone is insufficient to map legal equivalents).
What is the likely patent scope in US practice terms?
Clinical workflow captured
- Patient selection: human individual, with use in Claim 4 specifically for LQTS.
- Sample testing: obtain specimen and characterize CERKL expression product.
- Genotyping: evaluate rs993648; optionally evaluate CYP2D6 genotype for Claim 5.
- Dosing decision:
- If CERKL expression product and rs993648 status indicate no increased QT risk, dose to the first quantity (with one dependent claim specifying 24 mg/day).
- If CERKL expression product and rs993648 status indicate increased QT risk, reduce dose to a second quantity lower than the first (with dependent claim stating < 24 mg/day).
What is explicitly not required in the provided claim set
From the claim set alone, the following are not explicitly required:
- a specific QT measurement endpoint (eg, QTc change magnitude) within the method steps
- a specific lab modality for CERKL expression characterization
- exact reduced-dose value other than “less than” first quantity
How to read the rs993648 limitation: what is the “AG” vs “non-AG” switch doing?
Claim 1 uses the rs993648 locus to define which genotype is “not associated” with increased QT prolongation and which is “associated.”
- AG genotype → “not associated” with increased QT prolongation
- non-AG genotype → “associated” with increased QT prolongation
This places rs993648 not as an ancillary marker but as a gate that determines which dosing branch aligns with the claim’s “increased risk” conditional. In other words, even if CERKL expression product is characterized, the genotype limitation ties the claim’s risk association to specific rs993648 genotype classes.
Key takeaways for business and R&D teams
- US 10,570,453 Claim 1 is a conditional dosing method for iloperidone guided by CERKL expression product characterization plus a rs993648 genotype (AG vs non-AG) QT-risk mapping, requiring dose reduction when QT risk is increased.
- Claim 2 anchors a specific first dose (24 mg/day) and Claim 3 requires the reduced dose to be below 24 mg/day.
- Claim 4 confines one dependent pathway to LQTS patients; Claim 5 adds CYP2D6 genotype determination as an additional step.
- In US FTO, the claim’s strict requirement for CERKL expression product characterization and the rs993648 mapping should be treated as the two most constraining claim elements for literal overlap analysis.
- The patent sits at the intersection of QT risk pharmacogenomics and metabolism-genotype workflows (via CYP2D6 in Claim 5) but uniquely anchors QT-risk to CERKL/rs993648, not only to exposure.
FAQs
-
Does Claim 1 cover methods that use rs993648 genotype without measuring CERKL expression?
The provided Claim 1 language requires characterizing a CERKL expression product from a specimen, so a genotype-only method does not track the stated steps.
-
Is the dose reduction requirement numeric in Claim 1?
No. Claim 1 requires only that the second quantity is less than the first quantity. Numerical endpoints appear in dependent Claims 2 and 3.
-
What does Claim 4 add beyond Claim 1?
Claim 4 limits the method to individuals suffering from long QT syndrome (LQTS).
-
What additional step does Claim 5 introduce?
Claim 5 adds determining the individual’s CYP2D6 genotype.
-
Is iloperidone the only drug covered?
The claim covers administration of iloperidone, iloperidone metabolite, or pharmaceutically acceptable salts thereof.
References
[1] US Patent 10,570,453 (claim text as provided by user).
